Lilly (LLY) Completes Acquisition of Morphic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St advances on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices sink, shrugging off renewed Middle East fighting
- ASML capacity upgrade soothes AI chip bottleneck fears
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
August 16, 2024 8:39 AM EDTBroadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057
Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology
INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of... More
